It has been reported that MTX treatment can induce Immunogenic Cell Death (ICD) melanoma, osteosarcoma, and mouse colon cancer cells, acting through an eIF2α phosphorylation-dependent mechanism [24, 25]. This evidence concerns the gene EIF2A and osteosarcoma.